Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 9, Issue 4
February 25 2025
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

How donor age affects RBC deformability in storage
Kerryn Matthews,Hongshen Ma
View Articletitled, How donor age affects RBC deformability in storage
Testicular follicular lymphoma: let me count the ways
Elaine S. Jaffe,Leticia Quintanilla-Martinez
View Articletitled, Testicular follicular lymphoma: let me count the ways
The transplant debate: defining innovation for sickle cell
Cécile Karsenty,Titilope Fasipe,Alexander I. Ngwube
View Articletitled, The transplant debate: defining innovation for sickle cell
Hematology training in Africa: from brain drain to brain gain
Global Advances
Mary Ann Etling,Patrick T. McGann
View Articletitled, Hematology training in Africa: from brain drain to brain gain

ADVANCES VIEWPOINT

The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Clinical Trials & Observations
Alice Kuaban,Alysha K. Croker,Jeffrey Keefer,Leonard A. Valentino,Barbara E. Bierer,Stephen Boateng,Donna DiMichele,Patrick Fogarty,C. Michael Gibson,Anna M. Hood,Lloryn Hubbard,Antonella Isgrò,Karin Knobe,Leslie Lake,Iman Martin,Michel Reid,Jonathan C. Roberts,Wendy Tomlinson,Lanre Tunji-Ajayi,Harriette G.C. Van Spall,Caroline Voltz-Girolt,Allison P. Wheeler,Alan E. Mast,Stephanie Seremetis
View Articletitled, The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Supplemental data
New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials
Chijioke Nze,Alex F. Herrera
View Articletitled, New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials
Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
Clinical Trials & Observations
Richard J. Jones,Adetola A. Kassim,Robert A. Brodsky,Michael R. DeBaun
View Articletitled, Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
The transplant debate: defining innovation for sickle cell
Cécile Karsenty,Titilope Fasipe,Alexander I. Ngwube
View Articletitled, The transplant debate: defining innovation for sickle cell
Building capacity for pediatric hematological diseases in Sub-Saharan Africa
Lulu Chirande,Ruth Namazzi,Marilyn Hockenberry,Peter Wasswa,Sarah Kiguli,Tadala Mulemba,Julie M. Gastier-Foster,Magdalena Lyimo,Gladstone Airewele,Joseph Lubega,Nmazuo Ozuah
View Articletitled, Building capacity for pediatric hematological diseases in Sub-Saharan Africa
Hematology training in Africa: from brain drain to brain gain
Global Advances
Mary Ann Etling,Patrick T. McGann
View Articletitled, Hematology training in Africa: from brain drain to brain gain

REVIEW ARTICLES

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Gustavo de Oliveira Canedo,Claire Roddie,Persis J. Amrolia
View Articletitled, Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Nicola Maciocia,Brandon Wade,Paul Maciocia
View Articletitled, CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Clinical Trials & Observations
Elise A. Chong,Elicia Penuel,Ellen B. Napier,Rachel K. Lundberg,Lihua E. Budde,Mazyar Shadman,Matthew J. Matasar,Nancy L. Bartlett,Ian W. Flinn,Francesc Bosch,Keith Fay,Andre Goy,Anita Kumar,Loretta J. Nastoupil,Michael C. Wei,Mei Wu,Shen Yin,Joseph A. Fraietta,Emeline R. Chong,Stephen J. Schuster
View Articletitled, Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Supplemental data
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Clinical Trials & Observations
Benjamin M. Heyman,Stephen S. Opat,Björn E. Wahlin,Meletios-Athanasios C. Dimopoulos,Jorge J. Castillo,Alessandra Tedeschi,Constantine S. Tam,Christian Buske,Roger G. Owen,Véronique Leblond,Judith Trotman,Gisoo Barnes,Wai Y. Chan,Jingjing Schneider,Heather Allewelt,Aileen Cohen,Jeffrey V. Matous
View Articletitled, Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Clinical Trials & Observations
Matthew S. Davids,Danielle M. Brander,Yesid Alvarado-Valero,Catherine S. Diefenbach,Daniel N. Egan,Shira N. Dinner,Nathalie Javidi-Sharifi,Monzr M. Al Malki,Kebede H. Begna,Vijaya Raj Bhatt,Sameem Abedin,Rachel J. Cook,Mary C. Collins,Carly Roleder,Edward C. Dominguez,Prabhu Rajagopalan,Sandra E. Wiley,Richard G. Ghalie,Alexey V. Danilov
View Articletitled, A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Supplemental data
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Clinical Trials & Observations
Ying Wang,Lulu Lv,Yongping Song,Xudong Wei,Hongsheng Zhou,Qifa Liu,Kailin Xu,Dongmei Yan,Cheng Zhang,Shuangyou Liu,Jie Jin,Heng Mei,Ting Niu,Aibin Liang,Runxia Gu,Jienan Ren,Yi Feng,Wei Jin,Yan Zhou,Yiping Deng,Jianxiang Wang
View Articletitled, Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Supplemental data
Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome
Clinical Trials & Observations
Harinder Gill,Radha Raghupathy,Hsin-An Hou,Xavier Cheng-Hong Tsai,Adisak Tantiworawit,Melissa G. Ooi,Gin-Gin Gan,Chieh-Lee Wong,Rita Yim,Lynn Chin,Paul Lee,Vivian W.K. Li,Lester Au,Qi Zhang,Garret M.K. Leung,Tony K.Y. Wu,Carmen Y.Y. Lee,Wee-Joo Chng,Hwei-Fang Tien,Cyrus R. Kumana,Yok-Lam Kwong
View Articletitled, Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome
Supplemental data
Prognostic impact of patient-reported symptoms in multiple myeloma
Clinical Trials & Observations
Nadine Abdallah,Arwa Bohra,Aytaj Mammadzadeh,Francis Buadi,Prashant Kapoor,Angela Dispenzieri,Morie Gertz,Suzanne Hayman,Mohammed ElHaj,David Dingli,Joselle Cook,Moritz Binder,Yi Lin,Taxiarchis Kourelis,Rahma Warsame,Carrie Thompson,Terri Menser,S. Vincent Rajkumar,Shaji Kumar
View Articletitled, Prognostic impact of patient-reported symptoms in multiple myeloma
Supplemental data
Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study
Clinical Trials & Observations
Elisabeth Reuben Tolley,Torsten Holm Nielsen,Ditte Stampe Hersby,Simon Østergaard,Malin Rasmussen,Michael Roost Clausen,Ahmed Ludvigsen Al-Mashhadi,Karina Moeslund Egeberg,Laura Mors Haunstrup,Christian Brieghel,Carsten Utoft Niemann,Tarec Christoffer El-Galaly,Lars Møller Pedersen
View Articletitled, Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study
Supplemental data
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates
Clinical Trials & Observations
Ana Rita da Fonseca,Caio Cesar Justino,Vinicius Campos de Molla,Patricia Eiko Yamakawa,Iara Baldim Rabelo,Louise Arnold,Richard Kelly,Morag Griffin,Talha Munir,Anita Hill,Elvira Velloso,Thales Dalessandro,Antonio M. Risitano,Phillip Scheinberg,Austin Kulasekararaj,Celso Arrais-Rodrigues
View Articletitled, Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates

LYMPHOID NEOPLASIA

Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience
Steven R. Hwang,Richard C. Godby,Brianna J. Negaard,Raphael Mwangi,Adrienne N. Nedved,Jason N. Barreto,Ivana N. Micallef,Stephen M. Ansell,Luis Porrata,Urshila Durani,Gita Thanarajasingam,Thomas M. Habermann,Matthew J. Maurer,Patrick B. Johnston,Arushi Khurana
View Articletitled, Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience

MYELOID NEOPLASIA

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Thomas Cluzeau,Fabio Guolo,Edmond Chiche,Paola Minetto,Ramy Rahme,Sarah Bertoli,Luana Fianchi,Jean-Baptiste Micol,Michele Gottardi,Pierre Peterlin,Sara Galimberti,Xavier Thomas,Giuliana Rizzuto,Olivier Legrand,Michela Rondoni,Emmanuel Raffoux,Giambattista Bertani,Alexis Caulier,Michelina D’Argenio,Caroline Bonmati,Atto Billio,Caroline Lejeune,Barbara Scappini,Arnaud Pigneux,Patrizia Zappasodi,Christan Recher,Francesco Grimaldi,Lionel Ades,Roberto M. Lemoli
View Articletitled, Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia
Valeriya Kuznetsova,Vaidehi Krishnan,Amanda Costa,Xi Ren,Tiffany D. Ricketts,Sweta B. Patel,Ashley N. Connelly,Paran Goel,Joshua P. Knapp,Alana M. Franceski,Francesca Luca,Lorena Lobo de Figueiredo-Pontes,Ravi Bhatia,Shyam Prabhakar,S. Tiong Ong,Robert S. Welner
View Articletitled, Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia
Supplemental data
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen,Koji Sasaki,Farhad Ravandi,Tapan M. Kadia,Sa A. Wang,Wei Wang,Sanam Loghavi,Naval G. Daver,Courtney D. DiNardo,Ghayas C. Issa,Hussein A. Abbas,Cedric Nasnas,Alex Bataller,Samuel Urrutia,Omer S. Karrar,Sherry Pierce,Hagop M. Kantarjian,Nicholas J. Short
View Articletitled, Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Supplemental data
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
Damien Luque Paz,Nico Gagelmann,Lina Benajiba,Jérémie Riou,Rachel Salit,Corentin Orvain,Thomas Schroeder,Claire Bories,Carmelo Gurnari,Anita Badbaran,Françoise Boyer,Simona Pagliuca,Christina Rautenberg,Suzanne Tavitian,Victoria Pangiota,Jean-Christophe Ianotto,Felicitas Thol,Emilie Cayssials,Michael Heuser,Marie-Thérèse Rubio,Bruno Cassinat,Rafael Daltro de Oliveira,Craig Sauter,Jaroslaw P. Maciejewski,Hans Christian Reinhardt,Bart L. Scott,Valérie Ugo,Nicolaus Kröger,Jean-Jacques Kiladjian,Marie Robin
View Articletitled, Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
Supplemental data
TIFAB modulates metabolic pathways in KMT2A::MLLT3−induced AML through HNF4A
Yang Wang,Yan Xiu,Qianze Dong,Jinming Zhao,Kelao Neumbo,Masaru Miyagi,Nicholas Borcherding,Lin Fu,Havana De Celis,Nicolas Pintozzi,Daniel T. Starczynowski,Chen Zhao
View Articletitled, TIFAB modulates metabolic pathways in KMT2A::MLLT3−induced AML through HNF4A
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution
Olga Mykhailova,Mackenzie Brandon-Coatham,Sanaz Hemmatibardehshahi,Mahsa Yazdanbakhsh,Carly Olafson,Qi-Long Yi,Tamir Kanias,Jason P. Acker
View Articletitled, Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution
Supplemental data
How donor age affects RBC deformability in storage
Kerryn Matthews,Hongshen Ma
View Articletitled, How donor age affects RBC deformability in storage

THROMBOSIS AND HEMOSTASIS

Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X
Melanie P. Muller,Alex Mortenson,Josepha C. Sedzro,Po-Chao Wen,James H. Morrissey,Emad Tajkhorshid
View Articletitled, Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X
Supplemental data

TRANSPLANTATION

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Clinical Trials & Observations
Krzysztof Kalwak,Laura M. Moser,Ulrike Pötschger,Peter Bader,Katharina Kleinschmidt,Roland Meisel,Jean-Hugues Dalle,Akif Yesilipek,Adriana Balduzzi,Gergely Krivan,Evgenios Goussetis,Raquel Staciuk,Petr Sedlacek,Herbert Pichler,Peter Svec,Melissa Gabriel,Tayfun Güngör,Ernest Bilic,Jochen Buechner,Marleen Renard,Kim Vettenranta,Marianne Ifversen,Cristina Diaz-de-Heredia,Jerry Stein,Jacek Toporski,Marc Bierings,Christina Peters,Marc Ansari,Franco Locatelli
View Articletitled, Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Supplemental data

RESEARCH LETTERS

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
Clinical Trials & Observations
Sabine Khalife-Hachem,Arnaud Pages,Elie Akoury,Sarah Bonnet,Rudy Birsen,Clémence Busquet,Adrien Contejean,Alina Danu,Stéphane de Botton,Marie de Charette,Pierre Yves Dumas,Arnaud Jaccard,Anne Marfaing-Koka,Christophe Willekens,Eric Deconinck,David Ghez
View Articletitled, Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies
Tusneem Janoudi,Mrunali Jagdale,Meng Wu,Sanjana Gorlla,Peisheng Zhang,Ying Shao,Li Li,Sheryl R. Bowley,Eugenio Marco,Kai-Hsin Chang
View Articletitled, Nonclinical evaluation of <em>HBG1/2</em> and <em>BCL11A</em> as genome-editing targets for the treatment of β-hemoglobinopathies
Supplemental data
Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations
Weiwei Zhang,Anamarija M. Perry,Hans Magne Hamnvåg,Sumire K. Kitahara,Sarah L. Ondrejka,Alexandra E. Kovach,Ji Yuan,Krystie Chew,Julia Davidson,Victoria Bedell,Jamie L. Stokke,Joo Y. Song
View Articletitled, Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/<em>TNFRSF14</em> alterations
Supplemental data
Testicular follicular lymphoma: let me count the ways
Elaine S. Jaffe,Leticia Quintanilla-Martinez
View Articletitled, Testicular follicular lymphoma: let me count the ways
Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia
Shan Lin,Michael Kotliar,Sushmitha Vallabh,Anetta Ptasinska,Salam A. Assi,Mark Wunderlich,Constanze Bonifer,Artem Barski,James C. Mulloy
View Articletitled, Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia
Supplemental data
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Clinical Trials & Observations
Samer Al Hadidi,Obada Ababneh,Carolina Schinke,Sharmilan Thanendrarajan,Clyde Bailey,Robert Smith,Susan Panozzo,Daisy Alapat,Guido Tricot,John Shaughnessy, Jr.,Fenghuang Zhan,Jeffrey Sawyer,Eric R. Siegel,Bart Barlogie,Frits van Rhee,Maurizio Zangari
View Articletitled, Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Supplemental data

LETTER TO THE EDITOR

Generalized additive logit models for clinical prediction
Cameron Norman McIntosh
View Articletitled, Generalized additive logit models for clinical prediction

RESPONSE

GALMs confirm predictive power of thromboinflammation in STEMI
Clinical Trials & Observations
Karin Alde,Marcel Benkhoff,Amin Polzin
View Articletitled, GALMs confirm predictive power of thromboinflammation in STEMI
  • Cover Image

    Cover Image

    issue cover

    Molecular dynamics simulation of the membrane-bound enzyme that triggers blood clotting (tissue factor is shown in blue and factor VIIa in orange) bound to its favored substrate, factor X (purple). The proteins are assembled on a phospholipid bilayer. See the article by Muller et al.

All Issues

Advertisement intended for health care professionals

Ubiquitous clot contraction blockers hit ubiquitin and more
Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report
Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma
Impact of clinical factors on accuracy of ovarian cancer detection via platelet RNA profiling
Integrative cytogenetic and molecular studies unmask “chromosomal mimicry” in hematologic malignancies

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals